CA3225613A1 - Actrii proteins and uses thereof - Google Patents

Actrii proteins and uses thereof Download PDF

Info

Publication number
CA3225613A1
CA3225613A1 CA3225613A CA3225613A CA3225613A1 CA 3225613 A1 CA3225613 A1 CA 3225613A1 CA 3225613 A CA3225613 A CA 3225613A CA 3225613 A CA3225613 A CA 3225613A CA 3225613 A1 CA3225613 A1 CA 3225613A1
Authority
CA
Canada
Prior art keywords
patient
polypeptide
actrii
telangiectasia
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3225613A
Other languages
English (en)
French (fr)
Inventor
Janethe De Oliveira Pena
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3225613A1 publication Critical patent/CA3225613A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA3225613A 2021-07-19 2022-07-18 Actrii proteins and uses thereof Pending CA3225613A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163223265P 2021-07-19 2021-07-19
US63/223,265 2021-07-19
PCT/US2022/037479 WO2023003815A1 (en) 2021-07-19 2022-07-18 Actrii proteins and uses thereof

Publications (1)

Publication Number Publication Date
CA3225613A1 true CA3225613A1 (en) 2023-01-26

Family

ID=84979535

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3225613A Pending CA3225613A1 (en) 2021-07-19 2022-07-18 Actrii proteins and uses thereof

Country Status (18)

Country Link
US (1) US20240327494A1 (https=)
EP (1) EP4373577A4 (https=)
JP (1) JP2024526820A (https=)
KR (1) KR20240049857A (https=)
CN (1) CN117957014A (https=)
AU (1) AU2022316103A1 (https=)
CA (1) CA3225613A1 (https=)
CL (1) CL2024000151A1 (https=)
CO (1) CO2024001551A2 (https=)
CR (1) CR20240061A (https=)
DO (1) DOP2024000016A (https=)
EC (1) ECSP24012819A (https=)
GE (1) GEAP202416461A (https=)
IL (1) IL310141A (https=)
JO (1) JOP20240010A1 (https=)
MX (1) MX2024000829A (https=)
PE (1) PE20240777A1 (https=)
WO (1) WO2023003815A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
IL296394A (en) 2020-03-20 2022-11-01 Keros Therapeutics Inc Type ii activin receptor chimeras and methods of using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180055822A1 (en) * 2015-03-13 2018-03-01 Repoceuticals Aps Melatonin for Preventing and Treating Radiation Cystitis
CA3005975A1 (en) * 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
HRP20210694T1 (hr) * 2016-07-15 2021-09-17 Acceleron Pharma, Inc. Pripravci koji sadrže actriia polipeptide za uporabu za liječenje plućne hipertenzije

Also Published As

Publication number Publication date
CR20240061A (es) 2024-05-02
EP4373577A4 (en) 2025-05-14
CL2024000151A1 (es) 2024-08-09
JP2024526820A (ja) 2024-07-19
WO2023003815A9 (en) 2023-05-11
KR20240049857A (ko) 2024-04-17
PE20240777A1 (es) 2024-04-17
IL310141A (en) 2024-03-01
WO2023003815A1 (en) 2023-01-26
AU2022316103A1 (en) 2024-02-08
EP4373577A1 (en) 2024-05-29
ECSP24012819A (es) 2024-03-01
US20240327494A1 (en) 2024-10-03
GEAP202416461A (en) 2024-04-25
JOP20240010A1 (ar) 2024-01-18
MX2024000829A (es) 2024-04-12
CO2024001551A2 (es) 2024-03-07
CN117957014A (zh) 2024-04-30
DOP2024000016A (es) 2024-06-16

Similar Documents

Publication Publication Date Title
US20250249070A1 (en) Actrii proteins for the treatment of pulmonary arterial hypertension (pah)
US8287868B2 (en) BMP10 antibodies and related methods
US12583906B2 (en) Actrii proteins and use in treating post-capillary pulmonary hypertension
US20240299493A1 (en) Compositions and methods for treating pulmonary hypertension
US20240327494A1 (en) Actrii proteins and uses thereof
WO2022150590A1 (en) Compositions and methods for treating pulmonary hypertension
US20240174733A1 (en) Actrii proteins and uses thereof
US20240277806A1 (en) Actrii proteins and uses thereof
JP7854402B2 (ja) 肺動脈性肺高血圧症（ｐａｈ）の処置のためのａｃｔｒｉｉタンパク質
JP7851259B2 (ja) Ａｃｔｒｉｉタンパク質および後毛細管性肺高血圧症の処置における使用
WO2022261437A2 (en) Actrii proteins and uses thereof
EA053061B1 (ru) БЕЛКИ ActRII ДЛЯ ЛЕЧЕНИЯ ЛЕГОЧНОЙ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ (РАН)
EA049479B1 (ru) БЕЛКИ ActRII И ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ПОСТКАПИЛЛЯРНОЙ ЛЕГОЧНОЙ ГИПЕРТЕНЗИИ

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250616

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250616